The combination of immune checkpoint blockade and chemotherapy seems to be beneficial especially in patients with low levels of PD-L1 expressing tumor cells and ongoing trials are reporting positive results of this regimen in patients with resectable lung cancer6,9. The gene discussed is CD274; the disease is neoplasm.